Marchés français ouverture 9 h

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Cours en temps réel. Devise en USD
Ajouter à la liste dynamique
276,17-11,15 (-3,88 %)
À la clôture : 04:00PM EDT
276,10 -0,07 (-0,03 %)
Échanges après Bourse : 05:58PM EDT

Vertex Pharmaceuticals Incorporated

50 Northern Avenue
Boston, MA 02210
United States
617 341 6100
https://www.vrtx.com

Secteur(s)Healthcare
Secteur d’activitéBiotechnology
Employés à temps plein3 900

Dirigeants clés

NomTitrePayerExercéAnnée de naissance
Dr. Reshma Kewalramani FASN, M.D.CEO, Pres & Director4,27MS.O.1973
Mr. Charles F. Wagner Jr.Exec. VP & CFO1,85MS.O.1968
Mr. Stuart A. Arbuckle B.Sc.Exec. VP & COO2,56M197,69k1966
Dr. Ourania Tatsis Ph.D.Exec. VP and Chief Regulatory & Quality Officer1,33MS.O.1971
Ms. Kristen C. AmbroseChief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. ServicesS.O.S.O.1977
Dr. David M. Altshuler M.D., Ph.D.Exec. VP of Global Research & Chief Scientific OfficerS.O.S.O.1965
Mr. Mike TirozziSVP and Chief Information & Data OfficerS.O.S.O.S.O.
Mr. Michael PartridgeSr. VP of Investor RelationsS.O.S.O.S.O.
Mr. Damian W. Wilmot Esq.Sr. VP, Chief Risk and Compliance OfficerS.O.S.O.1976
Ms. Joy Liu J.D.Sr. VP & Gen. CounselS.O.S.O.1978
Les montants ont été établis en date du 31 décembre 2021 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Vertex Pharmaceuticals Incorporated en date du 1 juin 2022 est 7. Les scores principaux sont Audit : 9; Société : 5; Droits des actionnaires : 6; Compensation : 8.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.